As filed with the Securities and Exchange Commission on March 30, 2023
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Ambrx Biopharma Inc.
(Exact name of registrant as specified in its charter)
| Cayman Islands | Not applicable | |
(State or other jurisdiction of Incorporation or organization) | (I.R.S. Employer Identification No.) |
10975 North Torrey Pines Road
La Jolla, California 92037, United States
(Address of Principal Executive Offices) (Zip Code)
2021 Equity Incentive Plan
2021 Employee Share Purchase Program
(Full title of the plan)
Daniel O’Connor
President and Chief Executive Officer
Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, California 92037, United States
(858) 875-2400
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copy to:
Carlos Ramirez
Cooley LLP
10265 Science Center Drive
San Diego, California 92121
(858) 550-6000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
EXPLANATORY NOTE
This Registration Statement on Form S-8 (this “Registration Statement”) is being filed by Ambrx Biopharma Inc. (the “Registrant”) for the purpose of registering (i) an additional 13,522,762 ordinary shares (an equivalent of 1,931,823 American Depositary Shares) under the Ambrx Biopharma Inc. 2021 Equity Incentive Plan (the “2021 Plan”), pursuant to the provisions of the 2021 Plan which provide for annual automatic increases in the number of ordinary shares reserved for issuance under the 2021 Plan, and (ii) an additional 2,704,552 ordinary shares (an equivalent of 386,364 American Depositary Shares) under the Ambrx Biopharma Inc. 2021 Employee Share Purchase Program (the “2021 ESPP”), pursuant to the provisions of the 2021 ESPP which provide for annual automatic increases in the number of ordinary shares reserved for issuance under the 2021 ESPP. These additional ordinary shares are securities of the same class as other securities for which Registration Statements of the Registrant on Form S-8 relating to the same employee benefit plans are effective.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents By Reference.
The Registrant previously registered ordinary shares for issuance under the 2021 Plan and the 2021 ESPP pursuant to (i) a Registration Statement on Form S-8 (File No. 333-257264) filed with the Securities and Exchange Commission (the “Commission”) on June 22, 2021, and (ii) a Registration Statement on Form S-8 (File No. 333-264490) filed with the Commission on April 26, 2022 (collectively, the “Prior Registration Statements”). In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements are hereby incorporated by reference.
The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed by the Registrant with the Commission:
(a) the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Commission on March 30, 2023;
(b) the Registrant’s Current Reports on Form 8-K (other than information furnished rather than filed) filed with the Commission on January 30, 2023, February 6, 2023, February 17, 2023, February 24, 2023, March 1, 2023, March 6, 2023 and March 13, 2023; and
(c) the description of the Registrant’s ordinary shares in the registration statement on Form 8-A filed with the Commission on June 15, 2021, as amended on March 16, 2023, including any amendments or reports filed for the purpose of updating such description.
All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.
Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to specific section of such statements as set forth therein.
Under no circumstances shall any information furnished on Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.
Item 8. Exhibits.
| + | Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in La Jolla, California, on March 30, 2023.
| AMBRX BIOPHARMA INC. | ||
| By: | /s/ Daniel O’Connor | |
| Name: | Daniel O’Connor | |
| Title: | President and Chief Executive Officer | |
POWER OF ATTORNEY
KNOW ALL BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel O’Connor and Sonja Nelson, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Daniel O’Connor | President, Chief Executive Officer and Director (Principal Executive Officer) | March 30, 2023 | ||
| Daniel O’Connor | ||||
/s/ Sonja Nelson | Chief Financial and Operating Officer (Principal Financial Officer and Principal Accounting Officer) | March 30, 2023 | ||
| Sonja Nelson | ||||
/s/ Katrin Rupalla, Ph.D. | Chairperson of the Board of Directors | March 30, 2023 | ||
| Katrin Rupalla, Ph.D. | ||||
/s/ Xiaowei Chang, C.F.A | Director | March 30, 2023 | ||
| Xiaowei Chang, C.F.A. | ||||
/s/ Kate Hermans | Director | March 30, 2023 | ||
| Kate Hermans | ||||
/s/ Janet Loesberg, Pharm.D. | Director | March 30, 2023 | ||
| Janet Loesberg, Pharm.D. | ||||
/s/ Paul Maier | Director | March 30, 2023 | ||
| Paul Maier | ||||
SIGNATURE OF AUTHORIZED U.S. REPRESENTATIVE
Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of Ambrx Biopharma Inc., has signed this registration statement in La Jolla, California on March 30, 2023.
| Authorized U.S. Representative | ||
| Ambrx Biopharma Inc. | ||
| By: | /s/ Daniel O’Connor | |
| Name: | Daniel O’Connor | |
| Title: | President and Chief Executive Officer | |
